特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん分子診断の世界市場 - 戦略、動向、予測:2020年~2024年 (新型コロナウイルス感染症パンデミックによる景気後退予測を含む)

Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024

発行 Howe Sound Research 商品コード 932339
出版日 ページ情報 英文 334 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
がん分子診断の世界市場 - 戦略、動向、予測:2020年~2024年 (新型コロナウイルス感染症パンデミックによる景気後退予測を含む) Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024
出版日: 2020年04月16日 ページ情報: 英文 334 Pages
概要

分子診断 (MDx) 市場は、成長し続けています。がんの分子診断は、ゲノミクスの知識の急増から直接恩恵を受けるところまで来ています。がんのコンパニオン診断は、業界を再形成する新しい市場セグメントです。

当レポートでは、世界のがん分子診断市場について調査分析し、130社以上を対象に、市場戦略、動向、予測について、体系的な情報を提供しています。

目次

第1章 イントロダクションと市場の定義

  • 分子診断とは
  • 診断の革命
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査 - 見通し

第2章 市場概要

  • 市場参入企業
  • 市場セグメント
  • 業界構造

第3章 市場動向

  • 成長促進要因
  • 成長阻害要因
  • 計装と自動化
  • 診断技術の発展

第4章 分子診断の最近の発展

  • 最近の発展
  • コロナウイルスのパンデミックが欧州のがん研究に食い込む
  • VeracyteによるProsigna ID患者
  • CRISPRとナノポアシーケンシングの組み合わせ
  • リキッドバイオプシー
  • Roche、Illumina
  • Saga、Sevier、など

第5章 主要な分子診断 (MDx) 企業のプロファイル

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex、など
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack、など

第6章 世界のがんMDx市場

  • がんMDx - 世界市場の概要:国別

第7章 世界のがんMDx市場:がんの種類別

  • 世界市場:がんの種類別 - 概要
  • 乳がんMDx
  • 大腸がんMDx
  • 子宮頸がんMDx
  • 肺がんMDx
  • 前がん状態MDx
  • 黒色腫MDx
  • 血液MDx
  • コンパニオン診断MDx
  • その他のがんMDx

第8章 がん治療と治験

  • FDAの抗がん剤承認
  • 2010年~2016年に開始された治験
  • がん治療の有病率 - 2015年

付録

図表

Table of Tables

  • Table 1: Lab Spending 2014 to 2024
  • Table 2: Market Players by Type
  • Table 3: Clinical Laboratory Departments and Segments
  • Table 4: Laboratory Management Focus - Different Approaches
  • Table 5: Key Segmentation Variables Going Forward
  • Table 6: Five Factors Driving Growth
  • Table 7: Four Factors Limiting Growth
  • Table 8: Key Diagnostic Laboratory Technology Trends
  • Table 9: Next Generation Sequencing Technologies - Speed and Cost
  • Table 10: Global MDx Cancer Market by Region
  • Table 11: Global Market by Cancer Type
  • Table 12: MDx Breast Cancer by Country
  • Table 13: MDx Colorectal Cancer by Country
  • Table 14: Cervical Cancer Testing by Country
  • Table 15: Lung Cancer Testing by Country
  • Table 16: Prostate Testing by Country
  • Table 17: Melanoma Cancer Testing by Country
  • Table 18: MDx Blood by Country
  • Table 19: MDx Companion Dx Development by Country
  • Table 20: MDx Other Cancer Testing by Country
  • Table 21: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Growth in Aging Population
  • Figure 3: Death Rates from Cancer - USA
  • Figure 4: Comparing MDx Diagnostic and Traditional Testing
  • Figure 5: 2018 Global Market Density Chart
  • Figure 6: MDx Market by Cancer - Base vs. Final
  • Figure 7: Cancer Market Base Year
  • Figure 8: Cancer Market Final Year
  • Figure 9: MDx Cancer Share by Year
  • Figure 10: Breast Cancer Testing Growth
  • Figure 11: Colorectal Cancer Testing Growth
  • Figure 12: Cervical Cancer Testing Growth
  • Figure 13: Lung Cancer Testing Growth
  • Figure 14: Prostate Testing Growth
  • Figure 15: Melanoma Cancer Testing Growth
  • Figure 16: Blood Testing Growth
  • Figure 17: Companion Dx Development Growth
  • Figure 18: Other Cancer Testing Growth
  • Figure 19: FDA Cancer Drug Approvals by Year
  • Figure 20: Clinical Trials for Immunotherapy by Year
  • Figure 21: Pie Chart of Prevalence of Cancer Treatments
目次

OVERVIEW:

A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from Howe Sound Research. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. Our latest numbers factor in the different COVID forces and their timing. And their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

" Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024" provides data that analysts and planners can use.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Driven Recession

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What is Molecular Diagnostics
  • 1.2. The Diagnostics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Genomic Instrumentation Supplier
    • 2.1.4. Pharmaceutical/Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Lab
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Market Segments
    • 2.2.1. Traditional Market Segmentation
    • 2.2.2. Laboratory Focus and Segmentation
  • 2.3. Industry Structure
    • 2.3.1. Hospital Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. New Diagnostics Create New Markets
    • 3.1.2. New Roles for Diagnostics
    • 3.1.3. Longevity and Outcomes
    • 3.1.3. Expanding the Pharmaceutical Toolbox
    • 3.1.4. Regulatory Retreat
  • 3.2. Factors Limiting Growth
    • 3.2.1. Falling Prices
    • 3.2.2. Lower Costs
    • 3.2.3. Testing as a Controllable Cost
    • 3.2.4. Wellness has a Downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing
    • 3.4.2. Shifting Role of Diagnostics
    • 3.4.3. Multiplexing and Foundation One
    • 3.4.4. Pharmacogenomics Technology
    • 3.4.5. Whole Genome Sequencing
    • 3.4.6. Gene Editing and Gene Therapy

4. Molecular Diagnostics Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • Coronavirus Pandemic Bites into European Cancer Research
  • Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
  • Combining CRISPR and Nanopore Sequencing
  • Liquid Biopsy Detects Cancer Early via Cell Clusters
  • Roche, Illumina unveil 15-year cancer diagnostic tie-up
  • Saga, Servier Sign Liquid Biopsy Services Deal
  • Home urine test could revolutionize diagnosis of prostate cancer
  • Cancer Gene Tests Cost-Effective for Breast Cancer Patients
  • Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
  • OncoCyte to Buy Cancer Testing Company Razor Genomics
  • Blood Test May Eliminate Need for Exploratory Surgery
  • NGS Cancer Panel Receives New York State Conditional Approval
  • Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
  • Icon Acquires MolecularMD
  • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
  • Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune
  • Profiling Business
  • Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health
  • Business
  • UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
  • Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
  • Invitae Q3 Revenues More Than Double
  • Illumina to Acquire Pacific Biosciences
  • Lung Cancer Panel From PlexBio Receives CE Mark

5. Profiles of Key MDx Companies

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for MDx Cancer

  • 6.1. MDx Cancer - Global Market Overview by Country
    • 6.1.1. Table - Global Market by Country
    • 6.1.2. Chart - Global Market by Country

7. Global MDx Cancer Markets - By Type of Cancer

  • 7.1. Global Market by Cancer Type - Overview
    • 7.1.1. Table - Global Market by Cancer Type
    • 7.1.2. Chart - Global Market by Cancer Type - Base/Final Comparison
    • 7.1.3. Chart - Global Market by Cancer Type - Base Year
    • 7.1.4. Chart - Global Market by Cancer Type -Final Year
    • 7.1.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2. MDx Breast Cancer
    • 7.2.1. Table Breast Cancer Testing - by Country
    • 7.2.2. Chart - Breast Cancer Testing Growth
  • 7.3. MDx Colorectal Cancer
    • 7.3.1. Table Colorectal Cancer Testing - by Country
    • 7.3.2. Chart - Colorectal Cancer Testing Growth
  • 7.4. MDx Cervical Cancer
    • 7.4.1. Table Cervical Cancer Testing - by Country
    • 7.4.2. Chart - Cervical Cancer Testing Growth
  • 7.5. MDx Lung Cancer
    • 7.5.1. Table Lung Cancer Testing - by Country
    • 7.5.2. Chart - Lung Cancer Testing Growth
  • 7.6. MDx Precancer
    • 7.2.1. Table Prostate Testing - by Country
    • 7.6.2. Chart - Prostate Testing Growth
  • 7.7. MDx Melanoma Cancer
    • 7.7.1. Table Melanoma Cancer Testing - by Country
    • 7.7.2. Chart - Melanoma Cancer Testing Growth
  • 7.8. MDx Blood
    • 7.8.1. Table Blood Testing - by Country
    • 7.8.2. Chart - Blood Testing Growth
  • 7.9. MDx Companion Dx Development
    • 7.9.1. Table Companion Dx Development - by Country
    • 7.9.2. Chart - Companion Dx Development Growth
  • 7.10. MDx Other Cancer
    • 7.10.1. Table Other Cancer Testing - by Country
    • 7.10.2. Chart - Other Cancer Testing Growth

8. Cancer Treatment and Trials

  • 8.1. FDA Cancer Drug Approvals by
  • 8.2. Clinical Trials Started 2010 to 2016
  • 8.3. Prevalence of Cancer Treatments - 2015

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests